Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ben Ebede"'
Autor:
Giampaolo Merlini, Teresa Coelho, Márcia Waddington Cruz, Huihua Li, Michelle Stewart, Ben Ebede
Publikováno v:
Neurology and Therapy, Vol 9, Iss 1, Pp 105-115 (2020)
Abstract Introduction The effects of tafamidis on mortality in Val30Met and non-Val30Met patients with transthyretin amyloidosis with polyneuropathy (ATTR-PN) were evaluated. Methods The analyses were based on cumulative data from the Val30Met patien
Externí odkaz:
https://doaj.org/article/d3f649db1d9643eab617d4bb05bbdc9d
Autor:
Perry Elliott, Brian M Drachman, Stephen S Gottlieb, James E Hoffman, Scott L Hummel, Daniel J Lenihan, Ben Ebede, Balarama Gundapaneni, Benjamin Li, Marla B Sultan, Sanjiv J Shah
Publikováno v:
Future Cardiology. 19:7-17
What is this plain language summary about? This summary presents the results from an ongoing, long-term extension study that followed an earlier study called ATTR-ACT. People who took part in this extension study and ATTR-ACT have a type of heart dis
Autor:
Huihua Li, Ben Ebede, Jeffrey H. Schwartz, Marla B. Sultan, Peter Huber, Alison Flynn, Balarama Gundapaneni, Denise Rill
Publikováno v:
Amyloid. 26:203-209
Background: Tafamidis is approved in over 40 countries to delay neurologic progression in patients with transthyretin amyloid polyneuropathy (ATTR-PN). A comprehensive, integrated analysis of safety data from interventional, observational and surveil
Autor:
Márcia Waddington Cruz, Michelle Stewart, Ben Ebede, Teresa Coelho, Huihua Li, Giampaolo Merlini
Publikováno v:
Neurology and Therapy
Neurology and Therapy, Vol 9, Iss 1, Pp 105-115 (2020)
Neurology and Therapy, Vol 9, Iss 1, Pp 105-115 (2020)
Introduction: The effects of tafamidis on mortality in Val30Met and non-Val30Met patients with transthyretin amyloidosis with polyneuropathy (ATTR-PN) were evaluated. Methods: The analyses were based on cumulative data from the Val30Met patients in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3121414412b6116b9acad9f3ca7247bd
https://hdl.handle.net/10400.16/2685
https://hdl.handle.net/10400.16/2685
Autor:
Perry Elliott, Brian M. Drachman, Stephen S. Gottlieb, James E. Hoffman, Scott L. Hummel, Daniel J. Lenihan, Ben Ebede, Balarama Gundapaneni, Benjamin Li, Marla B. Sultan, Sanjiv J. Shah
Publikováno v:
Circulation. Heart Failure
Background: Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis
Autor:
Ben Ebede, Daniel J. Lenihan, James E. Hoffman, Scott L. Hummel, Brian M. Drachman, Perry M. Elliott, Marla B. Sultan, Stephen S. Gottlieb, Balarama Gundapaneni, Sanjiv J. Shah, Jeffrey H. Schwartz
Publikováno v:
European Heart Journal. 40
Background Transthyretin amyloid cardiomyopathy (ATTR-CM), is an underdiagnosed, fatal disease caused by the deposition of transthyretin amyloid fibrils in the heart leading to heart failure. The Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)
Autor:
Huihua Li, Fabio Barroso, Michelle Stewart, Leslie Amass, Marla B. Sultan, Ben Ebede, Daniel P. Judge
Background: The objective of the present study was to evaluate the long-term safety and efficacy of tafamidis in treating hereditary transthyretin amyloid polyneuropathy. Methods: A prospectively planned interim analysis was conducted on an on-going,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb91b9d39d595bce2955c3a257caa7ad